Migraine and headache in children and adolescents: A 2026 evidence-based factsheet
Open Access
- 6 August 2026
- journal article
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (8)
Abstract
Background: Headache disorders, particularly migraine, are among the leading causes of disability worldwide, with onset frequently occurring during childhood and adolescence. Despite their high prevalence and substantial functional impact, paediatric headache disorders remain under-recognised within health systems and under-represented in global policy frameworks. Methods: This factsheet was developed to provide a comprehensive, developmentally informed overview of the global burden of headache disorders in children and adolescents. It synthesises evidence from population-based studies, systematic reviews, clinical cohorts, and Global Burden of Disease (GBD) 2023 estimates. Key domains include epidemiology, disability burden, functional and psychosocial impacts, risk factors and triggers, diagnostic and treatment gaps, and current management strategies, with particular attention to disparities across sociodemographic groups. Results: According to GBD 2023 point-prevalence estimates, headache disorders increase markedly across development, from 10.71% among children aged 5–9 years to 42.64% among adolescents aged 15–19 years. Corresponding migraine prevalence estimates increase from 2.79% to 18.08%. GBD 2023 data also indicate that migraine is among the leading causes of years lived with disability from early life onwards.Migraine in children and adolescents is associated with substantial impairment in school attendance, academic performance, social participation, and quality of life. It is also frequently accompanied by psychiatric and somatic comorbidities. Access to timely diagnosis and evidence-based treatment remains highly inequitable, particularly in low- and middle-income countries. Emerging evidence suggests that adolescence may represent a critical window for intervention, with the potential to reduce progression to chronic migraine and long-term disability. Conclusions: Migraine and other headache disorders in children and adolescents constitute a major global public health challenge. This factsheet provides a comprehensive, evidence-based summary of their burden and highlights urgent priorities for policy integration, advocacy, and research. Early, equitable, and developmentally tailored care is essential to reduce lifelong disability and improve global brain health outcomes.Keywords
This publication has 51 references indexed in Scilit:
- Global, regional, and national burden of headache disorders, 1990–2021, with forecasts to 2050: A Global Burden of Disease study 2021Cell Reports Medicine, 2025
- Education and Social Life: The Impact of Headache on Participation in Children and Adolescents Attending a Headache Clinic—A Case-Control StudyPediatric Neurology, 2025
- Pediatric migraine care: bridging gaps, overcoming barriers, and advancing solutionsEuropean Journal of Pediatrics, 2025
- Preventive Medications in Pediatric MigraineJAMA Network Open, 2024
- More Than a Headache: Lived Experience of Migraine in YouthPediatric Neurology, 2023
- Anxiety and Depressive Symptoms and Disorders in Children and Adolescents With MigraineJAMA Pediatrics, 2022
- Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine ProphylaxisJAMA Pediatrics, 2020
- Nerve Blocks in Pediatric and Adolescent Headache DisordersCurrent Pain and Headache Reports, 2017
- Medical Comorbidities in Pediatric HeadacheSeminars in Pediatric Neurology, 2016
- Cognitive Behavioral Therapy Plus Amitriptyline for Chronic Migraine in Children and AdolescentsJAMA, 2013